PRESS RELEASE

NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced that it will report its third quarter financial results on Thursday, November 13, 2014 after the close of the U.S. financial markets. At 4:30 p.m. ET, Retrophin's management will host a conference call and webcast to discuss the company's financial results for the third quarter 2014 and provide a general business update.

Conference Call Information

A replay of the call will be available 7:30 p.m. ET, November 13, 2014 to 11:59 p.m., November 20, 2014. The replay number is 855-859-2056 (U.S.) or 404-537-3406 (International), confirmation code 26969110.

About Retrophin

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Thiola® and Vecamyl®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), schizophrenia, infantile spasms, nephrotic syndrome and others. For additional information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. No forward-looking statement can be guaranteed. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.

Retrophin, Inc.
Marc Panoff, 646-564-3671
CFO
marc@retrophin.com
or
Chris Cline, 646-564-3680
CFA Manager, Investor Relations
IR@retrophin.com

Source: Retrophin, Inc.

News Provided by Acquire Media